Vermillion to Present at the Canaccord Medical Technology & Diagnostics Forum
For the full press release please click here
AUSTIN, Texas, Nov. 12, 2018— Vermillion, Inc. (Nasdaq: VRML), a bio-analytical solutions company focused on gynecologic disease, announced today that Valerie Palmieri, President and Chief Executive Officer, and Robert Beechey, Chief Financial Officer, will present at the upcoming Canaccord Genuity Medical Technologies & Diagnostics Forum being held November 15, 2018 at the Westin Grand Central Hotel, New York, NY.
2018 Canaccord Genuity Medical Technologies & Diagnostics Forum
Date: Thursday, November 15, 2018
Time: 3:30 pm Eastern Time
Location: Westin Grand Central Hotel, New York
Vermillion, Inc. is dedicated to the discovery, development and commercialization of novel high-value diagnostic and bio-analytical solutions that help physicians diagnose, treat and improve gynecologic health outcomes for women. Vermillion, along with its prestigious scientific collaborators, discovers, develops, and delivers innovative diagnostic and technology tools that help women with serious diseases. The company’s initial in vitro diagnostic test, OVA1® (MIA), was the first FDA-cleared, protein-based In Vitro Diagnostic Multivariate Index Assay, and represented a new class of software-based liquid biopsy in vitro diagnostics. In March 2016, Vermillion received FDA clearance for Overa™, a Multivariate Index Assay 2nd Generation (MIA2G) test with significantly improved specificity and ease of use. For additional information, including published clinical trials, visit www.vermillion.com.
Investor Relations Contact:
LifeSci Advisors LLC